Examkin

Soru

Zorluk: OrtaNeoplastic Processes

A 61-year-old man is diagnosed with advanced non-small cell lung cancer. Immunohistochemical analysis of his biopsy specimen reveals a high tumor mutational burden and robust expression of programmed death-ligand 1 (PD-L1). He is initiated on pembrolizumab, an immune checkpoint inhibitor. The pathogenesis of this patient's pre-treatment immune evasion relies on a specific sequence of cellular interactions collectively known as adaptive immune resistance. Arrange the following pathophysiological events in the chronological order that leads to tumor-induced T-cell anergy.

  1. 1Dendritic cell cross-presentation of tumor-derived neoantigens to naive T cells.
  2. 2Infiltration of the tumor microenvironment by activated, neoantigen-specific cytotoxic CD8+ T cells.
  3. 3Secretion of pro-inflammatory cytokines, specifically interferon-gamma, by tumor-infiltrating lymphocytes.
  4. 4Adaptive upregulation of programmed death-ligand 1 (PD-L1) by malignant cells.
  5. 5Ligation of T-cell surface PD-1 receptors resulting in functional exhaustion and immune evasion.

Cevap

The correct sequence begins with dendritic cell presentation of neoantigens, followed by T-cell infiltration into the tumor, secretion of interferon-gamma by these T cells, subsequent adaptive upregulation of PD-L1 by the tumor cells, and finally the ligation of PD-1 receptors causing T-cell exhaustion.
The correct sequence describes the phenomenon of adaptive immune resistance. Initially, tumor cell turnover releases neoantigens that are taken up by dendritic cells and presented to naive T cells in the draining lymph nodes. These activated, antigen-specific CD8+ T cells then traffic to and infiltrate the tumor microenvironment. Upon recognizing their target antigens, the infiltrating T cells secrete pro-inflammatory cytokines, most notably interferon-gamma. In a counter-regulatory survival mechanism, the neoplastic cells respond to this local interferon-gamma exposure by adaptively upregulating PD-L1 on their cell surfaces. Finally, the newly expressed PD-L1 binds to PD-1 receptors on the activated T cells, sending an intracellular inhibitory signal that induces T-cell exhaustion, anergy, and apoptosis, thereby shielding the tumor from immune-mediated destruction.

Adım Adım Çözüm

1
Identify the initiating event of the anti-tumor immune response.
Dendritic cell cross-presentation of tumor-derived neoantigens.
Naive T cells require professional antigen-presenting cells in the lymphoid organs to become activated against novel tumor antigens.
2
Determine the required step following T-cell activation in the lymph nodes.
Infiltration of the tumor microenvironment by activated CD8+ T cells.
Activated T cells must physically traffic from the lymphoid tissue to the site of the neoplasm to exert their effector functions.
3
Identify the primary action of T cells upon recognizing the tumor.
Secretion of pro-inflammatory cytokines, specifically interferon-gamma.
Cytotoxic T cells release cytokines like interferon-gamma to orchestrate the destruction of the recognized malignant cells.
4
Recognize the tumor's counter-regulatory cellular response.
Adaptive upregulation of programmed death-ligand 1 (PD-L1).
Tumors utilize the interferon-gamma signal to adaptively upregulate PD-L1, attempting to subvert the ongoing immune attack.
5
Identify the final mechanism of action for T-cell suppression.
Ligation of T-cell surface PD-1 receptors resulting in functional exhaustion.
PD-L1 binding to the PD-1 checkpoint receptor directly halts T-cell proliferation and cytotoxic activity, completing the immune evasion sequence.

Anahtar Kavram

The mechanism of adaptive immune resistance and dynamic PD-L1 upregulation within the tumor microenvironment.
Bu soruyu puanla

Konular

Neoplastic Processes

Bu konudan daha fazla soru